Boston Scientific Corporation
BSX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $144,658,371 | $158,805,685 | $149,019,936 | $131,675,544 |
| - Cash | $0 | $534,000 | $725,000 | $414,000 |
| + Debt | $0 | $12,027,000 | $11,708,000 | $11,147,000 |
| Enterprise Value | $144,658,371 | $170,298,685 | $160,002,936 | $142,408,544 |
| Revenue | $5,065,000 | $5,061,000 | $4,663,000 | $4,561,000 |
| % Growth | 0.1% | 8.5% | 2.2% | – |
| Gross Profit | $3,542,000 | $3,424,000 | $2,950,000 | $2,671,000 |
| % Margin | 69.9% | 67.7% | 63.3% | 58.6% |
| EBITDA | $1,026,000 | $1,367,000 | $1,217,000 | $1,071,000 |
| % Margin | 20.3% | 27% | 26.1% | 23.5% |
| Net Income | $755,000 | $793,000 | $674,000 | $566,000 |
| % Margin | 14.9% | 15.7% | 14.5% | 12.4% |
| EPS Diluted | 0.5 | 0.53 | 0.451 | 0.38 |
| % Growth | -5.7% | 17.4% | 18.9% | – |
| Operating Cash Flow | – | $1,286,000 | $541,000 | $1,456,000 |
| Capital Expenditures | – | -$190,000 | -$187,000 | -$293,000 |
| Free Cash Flow | – | $1,096,000 | $354,000 | $1,163,000 |